Related Experiment Video
Updated: May 19, 2026
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples:
Michael Preukschas1, Christian Hagel, Alexander Schulte
1Department of Oncology, Haematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome. Despite a broad range of new and more specific treatment strategies, therapy of glioblastomas remains challenging and tumors relapse in all cases. Recent work demonstrated that the posttranslational hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is a crucial regulator of cell proliferation, differentiation and an important factor in tumor formation, progression and maintenance. Here we report that eIF-5A as well as the hypusine-forming enzymes deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) are highly overexpressed in glioblastoma patient samples. Importantly, targeting eIF-5A and its hypusine modification with GC7, a specific DHS-inhibitor, showed a strong antiproliferative effect in glioblastoma cell lines in vitro, while normal human astrocytes were not affected. Furthermore, we identified p53 dependent premature senescence, a permanent cell cycle arrest, as the primary outcome in U87-MG cells after treatment with GC7. Strikingly, combined treatment with clinically relevant alkylating agents and GC7 had an additive antiproliferative effect in glioblastoma cell lines. In addition, stable knockdown of eIF-5A and DHS by short hairpin RNA (shRNA) could mimic the antiproliferative effects of GC7. These findings suggest that pharmacological inhibition of eIF-5A may represent a novel concept to treat glioblastomas and may help to substantially improve the clinical course of this tumor entity.
Insights
Targeting eukaryotic initiation factor 5A (eIF-5A) and its hypusine modification with GC7 inhibits glioblastoma cell proliferation. This novel strategy, showing additive effects with chemotherapy, offers a promising new treatment for aggressive brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Glioblastomas are aggressive adult brain tumors with poor outcomes, often relapsing despite advanced treatments.
- The hypusine modification of eukaryotic initiation factor 5A (eIF-5A) is vital for cell proliferation and tumor progression.
- eIF-5A and its modifying enzymes (DHS, DOHH) are overexpressed in glioblastoma.
Purpose of the Study:
- To investigate the role of eIF-5A hypusome in glioblastoma.
- To evaluate the therapeutic potential of inhibiting eIF-5A hypusome formation in glioblastoma.
- To explore combination therapies involving eIF-5A inhibition.
Main Methods:
- Analysis of eIF-5A, DHS, and DOHH expression in glioblastoma samples.
- In vitro treatment of glioblastoma cell lines and normal astrocytes with DHS-inhibitor GC7.
- Assessment of cell proliferation, senescence induction (p53-dependent), and combination effects with alkylating agents.
- Stable knockdown of eIF-5A and DHS using shRNA.
Main Results:
- High expression of eIF-5A, DHS, and DOHH was observed in glioblastoma samples.
- GC7 demonstrated significant antiproliferative effects on glioblastoma cells, sparing normal astrocytes.
- GC7 induced p53-dependent premature senescence in U87-MG cells.
- Combined GC7 and alkylating agent treatment showed additive antiproliferative effects.
- shRNA-mediated knockdown of eIF-5A and DHS replicated GC7's effects.
Conclusions:
- Pharmacological inhibition of eIF-5A hypusome formation is a potential novel therapeutic strategy for glioblastoma.
- Targeting eIF-5A may improve the clinical management of glioblastoma.
- This approach warrants further investigation for glioblastoma treatment.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018